{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:44:19Z","timestamp":1790747059638,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["2020.0182"],"award-info":[{"award-number":["2020.0182"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007436","name":"Familjen Erling-Perssons Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101003653"],"award-info":[{"award-number":["101003653"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Serological testing is essential to curb the consequences of the COVID-19 pandemic. However, most assays are still limited to single analytes and samples collected within healthcare. Thus, we establish a multianalyte and multiplexed approach to reliably profile IgG and IgM levels against several versions of SARS-CoV-2 proteins (S, RBD, N) in home-sampled dried blood spots (DBS). We analyse DBS collected during spring of 2020 from 878 random and undiagnosed individuals from the population in Stockholm, Sweden, and use classification approaches to estimate an accumulated seroprevalence of 12.5% (95% CI: 10.3%\u201314.7%). This includes 5.4% of the samples being IgG\n                    <jats:sup>+<\/jats:sup>\n                    IgM\n                    <jats:sup>+<\/jats:sup>\n                    against several SARS-CoV-2 proteins, as well as 2.1% being IgG\n                    <jats:sup>\u2212<\/jats:sup>\n                    IgM\n                    <jats:sup>+<\/jats:sup>\n                    and 5.0% being IgG\n                    <jats:sup>+<\/jats:sup>\n                    IgM\n                    <jats:sup>\u2212<\/jats:sup>\n                    for the virus\u2019 S protein. Subjects classified as IgG\n                    <jats:sup>+<\/jats:sup>\n                    for several SARS-CoV-2 proteins report influenza-like symptoms more frequently than those being IgG\n                    <jats:sup>+<\/jats:sup>\n                    for only the S protein (OR\u2009=\u20096.1;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Among all seropositive cases, 30% are asymptomatic. Our strategy enables an accurate individual-level and multiplexed assessment of antibodies in home-sampled blood, assisting our understanding about the undiagnosed seroprevalence and diversity of the immune response against the coronavirus.\n                  <\/jats:p>","DOI":"10.1038\/s41467-021-23893-4","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T06:03:09Z","timestamp":1623909789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7147-6730","authenticated-orcid":false,"given":"Niclas","family":"Roxhed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9329-2353","authenticated-orcid":false,"given":"Annika","family":"Bendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5788-7744","authenticated-orcid":false,"given":"Matilda","family":"Dale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5514-2418","authenticated-orcid":false,"given":"Leo","family":"Hanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2875-896X","authenticated-orcid":false,"given":"Tea","family":"Dodig-Crnkovic\u0301","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birthe","family":"Meineke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8724-4849","authenticated-orcid":false,"given":"Simon","family":"Els\u00e4sser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juni","family":"Andr\u00e9ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Havervall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1345-6491","authenticated-orcid":false,"given":"Charlotte","family":"Th\u00e5lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Eklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8588-6506","authenticated-orcid":false,"given":"Joakim","family":"Dillner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6201-6380","authenticated-orcid":false,"given":"Cecilia E.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-7241","authenticated-orcid":false,"given":"Gerald","family":"McInerney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8603-8293","authenticated-orcid":false,"given":"Mun-Gwan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0393-4445","authenticated-orcid":false,"given":"Ben","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7674-2014","authenticated-orcid":false,"given":"Claudia","family":"Fredolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8141-8449","authenticated-orcid":false,"given":"Jochen M.","family":"Schwenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"23893_CR1","doi-asserted-by":"publisher","first-page":"eabc1931","DOI":"10.1126\/scitranslmed.abc1931","volume":"12","author":"R Weissleder","year":"2020","unstructured":"Weissleder, R., Lee, H., Ko, J. & Pittet, M. J. COVID-19 diagnostics in context. Sci. Transl. Med. 12, eabc1931 (2020).","journal-title":"Sci. Transl. Med"},{"key":"23893_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.virusres.2014.03.018","volume":"194","author":"B Meyer","year":"2014","unstructured":"Meyer, B., Drosten, C. & M\u00fcller, M. A. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res. 194, 175\u2013183 (2014).","journal-title":"Virus Res"},{"key":"23893_CR3","doi-asserted-by":"crossref","unstructured":"Klumpp-Thomas, C. et al.\u00a0Standardization of ELISA protocols for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling.\u00a0Nat. Commun.\u00a012,\u00a0113 (2021).","DOI":"10.1038\/s41467-020-20383-x"},{"key":"23893_CR4","doi-asserted-by":"publisher","unstructured":"Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-020-0913-5 (2020).","DOI":"10.1038\/s41591-020-0913-5"},{"key":"23893_CR5","doi-asserted-by":"crossref","unstructured":"Stringhini, S. et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.\u00a0Lancet 396,\u00a0313\u2013319 (2020).","DOI":"10.1016\/S0140-6736(20)31304-0"},{"key":"23893_CR6","doi-asserted-by":"crossref","unstructured":"Fontanet, A. et al. SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020. Euro. Surveill.\u00a026, 2001695 (2021).","DOI":"10.2807\/1560-7917.ES.2021.26.15.2001695"},{"key":"23893_CR7","doi-asserted-by":"crossref","unstructured":"Thompson, C. et al. Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. Euro Surveill. 25, 2000685 (2020).","DOI":"10.2807\/1560-7917.ES.2020.25.42.2000685"},{"key":"23893_CR8","doi-asserted-by":"crossref","unstructured":"Zamecnik, C. R. et al. ReScan, a multiplex diagnostic pipeline, pans human sera for SARS-CoV-2 antigens. Cell Rep. Med.\u00a01,\u00a0100123 (2020).","DOI":"10.1016\/j.xcrm.2020.100123"},{"key":"23893_CR9","doi-asserted-by":"crossref","unstructured":"Wang, H. et al. SARS-CoV-2 proteome microarray for mapping COVID-19 antibody interactions at amino acid resolution. ACS Cent. Sci.\u00a06, 2238\u20132249 (2020).\u00a0","DOI":"10.1021\/acscentsci.0c00742"},{"key":"23893_CR10","doi-asserted-by":"crossref","unstructured":"Jiang, H. et al. SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. Nat. Commun. 11, 3581\u00a0(2020).","DOI":"10.1038\/s41467-020-17488-8"},{"key":"23893_CR11","doi-asserted-by":"publisher","unstructured":"Norman, M. et al. Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19. Nat. Biomed. Eng. https:\/\/doi.org\/10.1038\/s41551-020-00611-x (2020).","DOI":"10.1038\/s41551-020-00611-x"},{"key":"23893_CR12","doi-asserted-by":"publisher","unstructured":"Shrock, E. et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science eabd4250 https:\/\/doi.org\/10.1126\/science.abd4250 (2020).","DOI":"10.1126\/science.abd4250"},{"key":"23893_CR13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.puhe.2020.04.009","volume":"182","author":"M D\u00f6hla","year":"2020","unstructured":"D\u00f6hla, M. et al. Rapid point-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity. Public Health 182, 170\u2013172 (2020).","journal-title":"Public Health"},{"key":"23893_CR14","doi-asserted-by":"crossref","unstructured":"Adams, E. R. et al. Antibody testing for COVID-19: a report from the National COVID Scientific Advisory Panel. Wellcome Open Res.\u00a05, 139 (2020).","DOI":"10.12688\/wellcomeopenres.15927.1"},{"key":"23893_CR15","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1038\/s41591-020-01144-1","volume":"26","author":"CA James","year":"2020","unstructured":"James, C. A., Barfield, M. D., Maass, K. F., Patel, S. R. & Anderson, M. D. Will patient-centric sampling become the norm for clinical trials after COVID-19? Nat. Med. 26, 1810 (2020).","journal-title":"Nat. Med."},{"key":"23893_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60703-1","volume":"10","author":"C Yamamoto","year":"2020","unstructured":"Yamamoto, C. et al. Evaluation of the efficiency of dried blood spot-based measurement of hepatitis B and hepatitis C virus seromarkers. Sci. Rep. 10, 3857 (2020).","journal-title":"Sci. Rep."},{"key":"23893_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/jimd.12163","volume":"43","author":"SJ Moat","year":"2020","unstructured":"Moat, S. J. et al. Performance of laboratory tests used to measure blood phenylalanine for the monitoring of patients with phenylketonuria. J. Inherit. Metab. Dis. 43, 179\u2013188 (2020).","journal-title":"J. Inherit. Metab. Dis."},{"key":"23893_CR18","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1097\/FTD.0000000000000659","volume":"41","author":"MA Zuur","year":"2019","unstructured":"Zuur, M. A. et al. Quality assessment of dried blood spots from patients with tuberculosis from 4 countries. Ther. Drug Monit. 41, 714\u2013718 (2019).","journal-title":"Ther. Drug Monit."},{"key":"23893_CR19","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.4155\/bio.15.134","volume":"7","author":"G Lenk","year":"2015","unstructured":"Lenk, G. et al. A disposable sampling device to collect volume-measured DBS directly from a fingerprick onto DBS paper. Bioanalysis 7, 2085\u20132094 (2015).","journal-title":"Bioanalysis"},{"key":"23893_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17425255.2018.1414181","volume":"14","author":"S Velghe","year":"2018","unstructured":"Velghe, S., De Troyer, R. & Stove, C. Dried blood spots in therapeutic drug monitoring and toxicology. Expert Opin. Drug Metab. Toxicol. 14, 1\u20133 (2018).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"23893_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18848-0","volume":"11","author":"A-S Rudberg","year":"2020","unstructured":"Rudberg, A.-S. et al. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. Nat. Commun. 11, 5064 (2020).","journal-title":"Nat. Commun."},{"key":"23893_CR22","unstructured":"The Public Health Agency of Sweden. P\u00e5visning av antikroppar efter genomg\u00e5ngen covid-19 i blodprov fr\u00e5n \u00f6ppenv\u00e5rden (Delrapport 1). https:\/\/www.folkhalsomyndigheten.se\/publicerat-material\/publikationsarkiv\/p\/pavisning-av-antikroppar-efter-genomgangen-covid-19-i-blodprov-fran-oppenvarden-delrapport-1 (2021)."},{"key":"23893_CR23","doi-asserted-by":"publisher","unstructured":"Dopico, X. C. et al. Seropositivity in blood donors and pregnant women during 9-months of SARS-CoV-2 transmission in Stockholm, Sweden. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.12.24.20248821 (2020)","DOI":"10.1101\/2020.12.24.20248821"},{"key":"23893_CR24","doi-asserted-by":"publisher","unstructured":"Griffith, G. et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.05.04.20090506 (2020)","DOI":"10.1101\/2020.05.04.20090506"},{"key":"23893_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20973-3","volume":"12","author":"M Becker","year":"2021","unstructured":"Becker, M. et al. Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. Nat. Commun. 12, 1152 (2021).","journal-title":"Nat. Commun."},{"key":"23893_CR26","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/s41591-020-0916-2","volume":"26","author":"C Menni","year":"2020","unstructured":"Menni, C. et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat. Med. 26, 1037\u20131040 (2020).","journal-title":"Nat. Med"},{"key":"23893_CR27","doi-asserted-by":"publisher","unstructured":"Gudbjartsson, D. F. et al. Humoral immune response to SARS-CoV-2 in Iceland. N. Engl. J. Med. NEJMoa2026116 https:\/\/doi.org\/10.1056\/NEJMoa2026116 (2020).","DOI":"10.1056\/NEJMoa2026116"},{"key":"23893_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/infdis\/jiaa659","volume":"223","author":"F Muecksch","year":"2021","unstructured":"Muecksch, F. et al. Longitudinal serological analysis and neutralizing antibody levels in Coronavirus disease 2019 convalescent patients. J. Infect. Dis. 223, 389\u2013398 (2021).","journal-title":"J. Infect. Dis."},{"key":"23893_CR29","doi-asserted-by":"publisher","unstructured":"Havervall, S. et al. SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection. https:\/\/doi.org\/10.1101\/2021.01.03.21249162 (2021).","DOI":"10.1101\/2021.01.03.21249162"},{"key":"23893_CR30","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","volume":"38","author":"CW Tan","year":"2020","unstructured":"Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2\u2013spike protein\u2013protein interaction. Nat. Biotechnol. 38, 1073\u20131078 (2020).","journal-title":"Nat. Biotechnol."},{"key":"23893_CR31","unstructured":"The Public Health Agency of Sweden. Confirmed COVID-19 cases in Sweden [accessed on 29 June 2020]; https:\/\/www.folkhalsomyndigheten.se\/smittskydd-beredskap\/utbrott\/aktuella-utbrott\/covid-19\/bekraftade-fall-i-sverige\/."},{"key":"23893_CR32","doi-asserted-by":"publisher","unstructured":"Kalish, H. et al. Mapping a pandemic: SARS-CoV-2 seropositivity in the United States. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.01.27.21250570 (2021).","DOI":"10.1101\/2021.01.27.21250570"},{"key":"23893_CR33","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"23893_CR34","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41594-020-0478-5","volume":"27","author":"The CITIID-NIHR COVID-19 BioResource Collaboration et al.","year":"2020","unstructured":"The CITIID-NIHR COVID-19 BioResource Collaboration et al. A thermostable, closed SARS-CoV-2 spike protein trimer. Nat. Struct. Mol. Biol. 27, 934\u2013941 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"23893_CR35","doi-asserted-by":"publisher","unstructured":"Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature https:\/\/doi.org\/10.1038\/s41586-020-2286-9 (2020).","DOI":"10.1038\/s41586-020-2286-9"},{"key":"23893_CR36","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1074\/mcp.M112.026757","volume":"12","author":"B Ayoglu","year":"2013","unstructured":"Ayoglu, B. et al. Autoantibody profiling in multiple sclerosis using arrays of human protein fragments. Mol. Cell Proteomics 12, 2657\u20132672 (2013).","journal-title":"Mol. Cell Proteomics"},{"key":"23893_CR37","unstructured":"R. Core Team. R: A Language and Environment for Statistical Computing (2018)."},{"key":"23893_CR38","unstructured":"Bezanson, J., Karpinski, S., Shah, V. B. & Edelman, A. Julia: a fast dynamic language for technical computing. Preprint at https:\/\/arxiv.org\/abs\/1209.5145 (2012)."},{"key":"23893_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1214\/aoms\/1177703732","volume":"35","author":"PJ Huber","year":"1964","unstructured":"Huber, P. J. Robust estimation of a location parameter. Ann. Math. Stat. 35, 73\u2013101 (1964).","journal-title":"Ann. Math. Stat."},{"key":"23893_CR40","doi-asserted-by":"publisher","unstructured":"Hong, M.-G. et al. Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2. Zenodo. https:\/\/doi.org\/10.5281\/ZENODO.4638597 (2021).","DOI":"10.5281\/ZENODO.4638597"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23893-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23893-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23893-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T08:01:11Z","timestamp":1669968071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23893-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["23893"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-23893-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.07.01.20143966","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]},"assertion":[{"value":"5 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"OB and NR are co-founders of Capitainer AB, a company that commercialized the blood collection device for microsampling. All other authors declare no conflicts of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3695"}}